Our Bioanalytical Department at Quinta-Analytica has expanded its analytical portfolio with a new Agilent 7850 ICP-MS system.

This addition increases our capacity for total elemental content in biological matrices and speciation analysis when coupled with HPLC, using ICP-MS as an element-specific detector.

Key applications include pharmacokinetic and bioequivalence studies of metal-based complexes or compounds used in treatments such as anemia, lung cancer, or bone cancer, as well as projects focused on various contrast agents used in imaging-based diagnostic methods.

An example of our work in this area can be found in the case study on total iron determination in human blood serum, available here.

Our analyses are routinely performed under GCP and GLP standards, with the option to provide GMP-compliant testing upon request. Currently, more than 7,000 ICP-MS analyses are scheduled through September 2025, reflecting the growing demand from our clients for advanced bioanalytical studies.

With this expanded setup, we offer for you not only increased capacity, but also faster project delivery and flexible support tailored to both early-phase studies and fully GMP-regulated programs.

 


Conscio group is a scientific service provider committed to improving the safety and quality of pharmaceuticals, food and our environment. Beyond clinical and analytical expertise, the Group offers GMP manufacturing solutions for investigational medicinal products (IMPs), as well as formulation development and technology transfer across multiple dosage forms. Learn more at www.conscio.group

Additional News

  • 7 August 2026

    Quinta-Analytica at CPHI Milan 2026 – Meet Us at Conscio Group Stand 6N25

    Meet Quinta-Analytica at CPHI Milan 2026 as part of the Conscio Group team at Stand 6N25. Discuss your clinical, bioanalytical and analytical projects with our experts and arrange a meeting in advance.

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.